SAN DIEGO, Feb. 24, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company will present at the following investor conferences:
- Citigroup 2011 Global Health Care Conference at 11:00 a.m. Eastern Time on Wednesday, March 2nd at the Hilton New York Hotel.
- Roth Capital Partners 23rd Annual OC Growth Stock Conference at 9:30 a.m. Pacific Time on Tuesday, March 15th at the Ritz-Carlton Laguna Niguel.
About Trius Therapeutics
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit .
CONTACT: Public Relations Contact: Jason Spark at Canale Communications, Inc. firstname.lastname@example.org 619-849-6005 Investor Relations Contact: Stefan Loren at Westwicke Partners, LLC email@example.com 443-213-0507